Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Indian-made ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...